JP5542282B2 - Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン - Google Patents

Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン Download PDF

Info

Publication number
JP5542282B2
JP5542282B2 JP2010515270A JP2010515270A JP5542282B2 JP 5542282 B2 JP5542282 B2 JP 5542282B2 JP 2010515270 A JP2010515270 A JP 2010515270A JP 2010515270 A JP2010515270 A JP 2010515270A JP 5542282 B2 JP5542282 B2 JP 5542282B2
Authority
JP
Japan
Prior art keywords
compound
enantiomer
alkyl
salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010515270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532387A5 (cg-RX-API-DMAC7.html
JP2010532387A (ja
Inventor
ジョセフ アール． ベンクシク，
ジェイムス エフ． ブレーク，
ニコラス シー． カラン，
イアン エス． ミッチェル，
キース エル． スペンサー，
デンミン シャオ，
ルイ スー，
クリスティン シャボー，
ユン リャン，
ブライアン エス． サフィーナ，
Original Assignee
アレイ バイオファーマ、インコーポレイテッド
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ、インコーポレイテッド, ジェネンテック， インコーポレイテッド filed Critical アレイ バイオファーマ、インコーポレイテッド
Publication of JP2010532387A publication Critical patent/JP2010532387A/ja
Publication of JP2010532387A5 publication Critical patent/JP2010532387A5/ja
Application granted granted Critical
Publication of JP5542282B2 publication Critical patent/JP5542282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2010515270A 2007-07-05 2008-07-03 Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン Active JP5542282B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94814707P 2007-07-05 2007-07-05
US60/948,147 2007-07-05
PCT/US2008/069147 WO2009006569A1 (en) 2007-07-05 2008-07-03 Pyrimidyl cyclopentanes as akt protein kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013249824A Division JP2014040489A (ja) 2007-07-05 2013-12-03 Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン

Publications (3)

Publication Number Publication Date
JP2010532387A JP2010532387A (ja) 2010-10-07
JP2010532387A5 JP2010532387A5 (cg-RX-API-DMAC7.html) 2012-07-26
JP5542282B2 true JP5542282B2 (ja) 2014-07-09

Family

ID=39830222

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010515270A Active JP5542282B2 (ja) 2007-07-05 2008-07-03 Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン
JP2013249824A Withdrawn JP2014040489A (ja) 2007-07-05 2013-12-03 Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013249824A Withdrawn JP2014040489A (ja) 2007-07-05 2013-12-03 Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン

Country Status (15)

Country Link
US (1) US8377937B2 (cg-RX-API-DMAC7.html)
EP (2) EP2173723B3 (cg-RX-API-DMAC7.html)
JP (2) JP5542282B2 (cg-RX-API-DMAC7.html)
KR (2) KR101624361B1 (cg-RX-API-DMAC7.html)
CN (1) CN101918373B (cg-RX-API-DMAC7.html)
AT (1) ATE522509T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008272832B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813993A2 (cg-RX-API-DMAC7.html)
CA (1) CA2692506C (cg-RX-API-DMAC7.html)
ES (1) ES2533557T3 (cg-RX-API-DMAC7.html)
IL (1) IL202617A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009014013A (cg-RX-API-DMAC7.html)
SI (1) SI2173723T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009006569A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908901B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150089099A (ko) * 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009089352A1 (en) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
JP5635910B2 (ja) 2008-01-09 2014-12-03 アレイ バイオファーマ、インコーポレイテッド ＡＫＴタンパク質キナーゼ阻害剤としての５Ｈ−シクロペンタ［ｄ］ピリミジン
JP5539225B2 (ja) 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン
US8372842B2 (en) 2008-01-09 2013-02-12 Array Biopharma Inc. Pyrazolopyridines as kinase inhibitors
GB201110546D0 (en) * 2011-06-22 2011-08-03 Imp Innovations Ltd Compositions
JP6214636B2 (ja) * 2012-05-17 2017-10-18 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
SG10202104386UA (en) 2016-10-28 2021-05-28 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
CA3092677A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
CN112996518A (zh) 2018-06-21 2021-06-18 西奈山伊坎医学院 Wd40重复结构域蛋白5(wdr5)降解/破坏化合物和使用方法
EP3965824B1 (en) 2019-05-06 2025-01-08 Icahn School of Medicine at Mount Sinai Heterobifunctional compounds as degraders of hpk1
BR112022017856A2 (pt) * 2020-03-17 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
TW202328138A (zh) 2021-09-17 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 稠合二環類衍生物的可藥用鹽、晶型及其製備方法
CN116514739B (zh) * 2023-05-09 2025-07-22 天津绿菱气体股份有限公司 一种1,4-二甲基哌嗪及其制备方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885035A (en) * 1972-04-05 1975-05-20 Sandoz Ag Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3956495A (en) * 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US3966936A (en) * 1974-02-21 1976-06-29 Pfizer Inc. Piperazino quinazoline bronchodilators
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
JPS562968A (en) * 1979-06-21 1981-01-13 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
JPS6270A (ja) 1985-03-07 1987-01-06 Sankyo Co Ltd シクロペンタ〔ｄ〕ピリミジン誘導体
WO1990007926A1 (en) * 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
KR100262254B1 (ko) * 1992-10-05 2000-07-15 나카히로 마오미 피리미딘 화합물
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE
GB9416189D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
RU2129549C1 (ru) * 1994-08-13 1999-04-27 Юхан Корпорейшн Производные пиримидина и способы их получения
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US7125880B1 (en) * 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501277A (en) 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
BR9810366A (pt) 1997-07-01 2000-08-29 Warner Lambert Co Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
WO1999051582A1 (en) * 1998-03-31 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
DE19853278A1 (de) * 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
HUP0104933A3 (en) 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
ATE292462T1 (de) 1999-01-07 2005-04-15 Warner Lambert Co Behandlung von asthma anhand von mek-inhibitoren
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
IL144215A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
IL144214A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
ES2252996T3 (es) 1999-01-13 2006-05-16 Warner-Lambert Company Llc Derivados de bencenosulfonamida y su uso como inhibidores de mek.
ATE311363T1 (de) 1999-01-13 2005-12-15 Warner Lambert Co Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
AU5785900A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
EP1202726A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
HUP0202180A3 (en) 1999-07-16 2004-10-28 Warner Lambert Co Method for treating chronic pain using mek inhibitors
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
YU2503A (sh) 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
JP2004507518A (ja) 2000-08-25 2004-03-11 ワーナー−ランバート・カンパニー・エルエルシー Ｎ−アリール−アントラニル酸及びその誘導体の製造法
JP2004509115A (ja) * 2000-09-15 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
ATE386727T1 (de) * 2001-04-30 2008-03-15 Glaxo Group Ltd Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf)
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478534A1 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003226250B2 (en) 2002-04-08 2007-08-16 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1496896A4 (en) * 2002-04-08 2007-10-31 Merck & Co Inc AKT INHIBITORS EFFECT
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
AU2003226271B2 (en) 2002-04-08 2007-10-18 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of Akt activity
MXPA04011093A (es) 2002-05-10 2005-02-14 Neurocrine Biosciences Inc Piperazina sustituida como ligandos de receptores de melanocortina.
US20050045867A1 (en) * 2002-10-30 2005-03-03 Ozkan Cengiz S. Nanoscale heterojunctions and methods of making and using thereof
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1428793B1 (en) * 2002-12-12 2011-02-09 Sony Deutschland GmbH Soluble carbon nanotubes
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EP1663994B1 (en) 2003-08-05 2012-03-07 Vertex Pharmaceuticals Incorporated Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
DE602004009200T2 (de) * 2003-08-12 2008-07-10 F. Hoffmann-La Roche Ag Tetrahydrochinazolinderivate als cfr-antagonisten
BRPI0414238A (pt) * 2003-09-09 2006-10-31 Ono Pharmaceutical Co antagonistas de crf e compostos heterobicìclicos
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
JP2007512364A (ja) * 2003-11-21 2007-05-17 アレイ バイオファーマ、インコーポレイテッド Ａｋｔプロテインキナーゼインヒビター
JP5213229B2 (ja) * 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
US7556746B2 (en) * 2004-06-03 2009-07-07 Nantero, Inc. Method of making an applicator liquid for electronics fabrication process
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
CA2590961C (en) * 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
JP2008531542A (ja) 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 抗癌剤として有用な二環式複素芳香族誘導体
WO2006127587A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
AR054485A1 (es) 2005-06-21 2007-06-27 Cancer Rec Tech Ltd ARIL-ALQUILAMINAS Y HETEROARIL-ALQUILAMINAS COMO INHIBIDORES DE PROTEINA QUINASA A Y B, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ORIGINADAS EN EL CRECIMIENTO ANORMAL DE LA
EP1948658A1 (en) 2005-10-13 2008-07-30 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
AR056893A1 (es) 2005-12-28 2007-10-31 Takeda Pharmaceutical Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
BRPI0714062A2 (pt) 2006-07-06 2012-12-18 Glaxo Group Ltd n-fenil-metil-5-oxo-prolina-2-amidas substituìdas como antagonistas do receptor da p2x, e os seus métodos de uso
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
GB0613518D0 (en) 2006-07-06 2006-08-16 Phytopharm Plc Chemical compounds
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
SI2049500T1 (sl) * 2006-07-06 2012-01-31 Array Biopharma Inc Ciklopenta (d) pirimidini kot AKT protein kinazni inhibitorji
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents

Also Published As

Publication number Publication date
CN101918373B (zh) 2013-06-05
HK1136832A1 (en) 2010-07-09
US20110160221A1 (en) 2011-06-30
SI2173723T1 (sl) 2011-12-30
ZA200908901B (en) 2011-10-26
KR20150091196A (ko) 2015-08-07
ATE522509T1 (de) 2011-09-15
US8377937B2 (en) 2013-02-19
IL202617A0 (en) 2010-06-30
AU2008272832A1 (en) 2009-01-08
KR20100029846A (ko) 2010-03-17
AU2008272832B2 (en) 2014-02-20
JP2010532387A (ja) 2010-10-07
CA2692506A1 (en) 2009-01-08
CA2692506C (en) 2015-11-24
EP2404907B1 (en) 2015-01-14
WO2009006569A1 (en) 2009-01-08
KR101624361B1 (ko) 2016-05-25
EP2173723A1 (en) 2010-04-14
HK1166078A1 (en) 2012-10-19
RU2010103811A (ru) 2011-08-10
EP2173723B1 (en) 2011-08-31
BRPI0813993A2 (pt) 2015-06-16
ES2533557T3 (es) 2015-04-13
EP2404907A1 (en) 2012-01-11
MX2009014013A (es) 2010-01-28
CN101918373A (zh) 2010-12-15
EP2173723B3 (en) 2014-11-19
JP2014040489A (ja) 2014-03-06

Similar Documents

Publication Publication Date Title
JP5542282B2 (ja) Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン
US8618097B2 (en) Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR101578877B1 (ko) ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR20150041164A (ko) Ａｋｔ 단백질 키나제 억제제로서의 시클로펜타〔ｄ〕피리미딘
US8846683B2 (en) Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
RU2486178C2 (ru) Пиримидилциклопентаны в качестве ингибиторов akt-протеинкиназы
HK1136832B (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors
HK1166078B (en) Pyrimidyl cyclopentanes as akt protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130903

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131003

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131101

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140506

R150 Certificate of patent or registration of utility model

Ref document number: 5542282

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250